Tirzepatide for Autonomous Cortisol Secretion

This trial tests whether tirzepatide can improve health outcomes for individuals with Mild Autonomous Cortisol Secretion (MACS) following adrenal gland surgery. MACS can lead to high blood pressure, diabetes, and weight gain, and some individuals continue to experience these issues post-surgery. The trial compares the effects of standard care with tirzepatide treatment. Suitable candidates for this trial have undergone or will undergo adrenal gland surgery, have high blood pressure, and a BMI of 27 or higher. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently using GLP-1 receptor agonists. It's best to discuss your specific medications with the trial team.

Research shows that tirzepatide is generally well-tolerated by patients. Earlier studies associated it with improved insulin sensitivity and weight loss, which benefit those with metabolic health issues. Some side effects, such as mild stomach problems, have been reported, but they are usually manageable and tend to lessen over time. Tirzepatide is already approved for treating type 2 diabetes, indicating a certain level of safety in humans. However, since this is a Phase 2 trial, the researchers aim to further confirm its safety and effectiveness for treating mild autonomous cortisol secretion.¹²³⁴⁵

Unlike the standard treatments for autonomous cortisol secretion, which typically involve surgery, medications like ketoconazole, or metyrapone, tirzepatide offers a novel approach by targeting the GLP-1 receptor. This treatment is unique because it acts as a dual agonist for the GLP-1 and GIP receptors, which could help in better regulating cortisol production. Researchers are excited about tirzepatide because it not only offers a potential new mechanism of action but also provides the convenience of a once-weekly injection, which could improve patient adherence compared to daily medication regimens.

Research has shown that tirzepatide can improve metabolic health. It significantly reduces body fat and enhances insulin use, which is crucial for managing weight and blood sugar levels. For individuals with conditions like mild autonomous cortisol secretion (MACS), these benefits could address issues such as high blood pressure and diabetes. In this trial, participants in the GLP-1 Treatment arm will receive tirzepatide. Studies indicate that it improves the function of insulin-producing cells. These findings suggest that tirzepatide might effectively enhance metabolic health after adrenal gland surgery.¹²³⁴⁶